Gilead and Galapagos close in on filing for Xeljanz rival - PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival  PMLiVE

Galapagos and Gilead Sciences have a pair of positive phase 3 trials for their JAK inhibitor filgotinib in rheumatoid arthritis that they say make it a contender in ...